Shaily Engineering Plastics Q1FY27 PAT up 46% to ₹52.47 cr

What stood out in Q1FY27

Shaily Engineering Plastics reported a sharp improvement in profitability in Q1FY27, led by a strong performance in its healthcare segment and better operating efficiency at its Gujarat facilities. Standalone profit after tax (PAT) rose 46% year-on-year (YoY) to ₹52.47 crore. Consolidated revenue from operations increased 14% YoY to ₹280.7 crore.

The company’s quarterly update points to a clear split in demand conditions across its portfolio. Healthcare revenue grew sharply, while consumer demand declined. Margin expansion at the consolidated level also indicates improved operating leverage and utilisation.

Key financial snapshot: standalone and consolidated

On the standalone basis, revenue from operations rose 22% YoY to ₹274.78 crore, compared with ₹225.10 crore in Q1FY26. Standalone PAT increased to ₹52.47 crore from ₹35.97 crore.

On the consolidated basis, PAT rose 17% YoY to ₹48.0 crore from ₹41.1 crore, while revenue increased to ₹280.7 crore from ₹246.7 crore. The difference between standalone and consolidated PAT growth suggests that subsidiary performance reduced the headline growth rate at the group level.

Cash PAT, defined as PAT plus depreciation, increased 18% to ₹62.1 crore.

Healthcare drives growth as consumer demand declines

The healthcare segment emerged as the main growth driver during the quarter. Segment revenue rose 85% to ₹142.4 crore in Q1FY27 from ₹77.2 crore in Q1FY26. The company indicated that this surge in healthcare revenue helped offset weakness in the consumer segment.

The update also notes a 24% decline in consumer demand, highlighting a mixed environment across end markets. While detailed consumer segment revenue numbers for Q1FY27 were not provided in the data, the stated demand decline is significant because it underlines that the quarter’s growth was not broad-based.

Margin expansion and operational efficiency

Consolidated EBITDA margin expanded by 120 basis points to 29.7% in Q1FY27 from 28.5% in Q1FY26. The company attributed this improvement to better operational efficiency and higher machine utilisation across its Gujarat facilities.

Gross profit margin also strengthened meaningfully at the consolidated level, rising to 56.6% from 51.2%, an improvement of 540 basis points. Taken together, the gross margin expansion and EBITDA margin improvement indicate that the company benefited from a more favourable mix and tighter cost absorption in the quarter.

Standalone vs consolidated: why the gap matters

A notable feature of the release is that standalone PAT grew faster than consolidated PAT. Standalone PAT increased 46% YoY, while consolidated PAT grew 17% YoY.

The company stated that subsidiary performance diluted overall growth slightly. This distinction matters for investors tracking group performance, because consolidated results reflect the full economic picture across the company’s operating structure.

Summary table of reported metrics

Stock, calendar events, and corporate actions

Shaily Engineering Plastics will host an earnings conference call on August 10, 2026 at 4:00 PM IST to discuss the operational and financial performance for the quarter ended June 30, 2026. The board meeting is scheduled for August 08, 2026 to consider the audited financial results for Q1 FY27.

The data also lists key calendar references: the stock result is marked for 8th Aug 2026 (Saturday) for Q1 FY 26-27 results, and a prior corporate action notes a final dividend of ₹2 per share dated 19th Sept 2025 (Friday).

On pricing, the share price is stated as ₹3,162.30 as of 07 Aug 2026 at 03:59 PM. Separate quick details in the provided data mention CMP at ₹3,061.4, and another section lists CMP at ₹2,888.

Ownership and balance sheet pointers in the dataset

As of Jun ’26, the company’s market capitalisation is stated at ₹14,545.08 crore, while another figure lists market cap at ₹14,080.99 crore. The latest-quarter net debt is listed as ₹148.86 crore.

Shareholding as of Jun ’26 shows promoters holding 41.1%, FIIs at 18.2%, DIIs at 14.8%, and public shareholders at 25.9%. This ownership mix is useful context around institutional participation, but it does not directly change the quarter’s reported financial outcome.

FY26 backdrop and recent quarterly history

In Q4FY26, the company reported a 40% YoY increase in PAT to ₹40 crore, supported by a 101% revenue surge in the healthcare segment. Revenue from operations in Q4FY26 rose 9% to ₹237 crore compared to ₹218 crore in the corresponding period of the previous year. EBITDA in Q4FY26 rose 27% to ₹69 crore, with margins expanding by 420 basis points to 29.3%.

For the full financial year FY26, the company recorded 26% revenue growth to ₹991 crore from ₹787 crore in FY25. PAT jumped 83% to ₹170 crore and EBITDA increased 61% to ₹288 crore.

Separately, the dataset also states that for the full year FY2026–2027, revenue reached ₹998.45 crore and profit touched ₹169.91 crore.

Market impact: what the numbers imply

The quarter’s core takeaway is that growth and profitability were powered by healthcare. Healthcare revenue growth of 85% to ₹142.4 crore helped offset a reported 24% decline in consumer demand, reinforcing the importance of segment mix in near-term performance.

From a profitability standpoint, consolidated margin expansion was material: EBITDA margin rose to 29.7% and gross profit margin rose to 56.6%. Alongside 14% YoY consolidated revenue growth to ₹280.7 crore, these margin gains helped lift consolidated PAT to ₹48.0 crore.

However, the divergence between standalone PAT growth (46%) and consolidated PAT growth (17%) highlights that investors should track both sets of numbers, particularly when subsidiary performance changes the pace of consolidated earnings.

What to watch next

The scheduled board meeting on August 08, 2026 and the earnings conference call on August 10, 2026 are the next formal checkpoints for management commentary. Investors typically look to such calls for clarity on segment demand, capacity utilisation, and the sustainability of margins.

The dataset also notes the upcoming earnings date for Shaily Engineering Plastics as 8th Aug, 2026, aligning with the Q1FY27 result timetable referenced in the corporate action section.

Conclusion

Shaily Engineering Plastics delivered strong Q1FY27 profitability, with standalone PAT rising 46% to ₹52.47 crore and consolidated revenue increasing 14% to ₹280.7 crore. Healthcare revenue growth of 85% to ₹142.4 crore remained the key driver, while consolidated margins improved with EBITDA margin at 29.7%.

The next update is expected through the board meeting on August 08, 2026 and the earnings call on August 10, 2026, where the company is scheduled to discuss the quarter ended June 30, 2026.